STAT NewsOriginal article
STAT+: Pharmalittle: We’re reading about FDA views on a Duchenne drug, GSK cost savings, and more
Phase 3negativeNegative
AI Analysis
Summary
The FDA determined that Capricor's stem cell treatment for Duchenne muscular dystrophy failed to meet Phase 3 trial objectives, contradicting the company's claims about the trial's success.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
FDA said the stem cell treatment did not meet Phase 3 trial objectives, contrary to company claims
Importance:7/10
Sentiment:
-0.80
FDAclinical trialDuchenne muscular dystrophystem cellnegative data
Related Companies
Read the original article
Published by STAT News on July 28, 2026 1:25 PM